We live in interesting times.
No one is really quite sure who said it, but it’s never been truer as we do live in very interesting times. Nearly every diabetes device maker is getting killed as everyone foolishly believes that these devices are no longer necessary since every patient will soon be using Ozempic or Mounjaro. Lilly and Novo Nordisk are doing so well they are like Pablo Escobar not knowing what to do with all the money they are making.
Tandem is getting sued so often that the soon to be gone management team can’t wait to be shown the door. The . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.